LT2643468T - Naujos signalinės sekos, skirtos baltymo raiškos ir rekombinantinių fermentų ir kitų baltymų sekrecijos pagerinimui - Google Patents

Naujos signalinės sekos, skirtos baltymo raiškos ir rekombinantinių fermentų ir kitų baltymų sekrecijos pagerinimui

Info

Publication number
LT2643468T
LT2643468T LTEP11843849.8T LT11843849T LT2643468T LT 2643468 T LT2643468 T LT 2643468T LT 11843849 T LT11843849 T LT 11843849T LT 2643468 T LT2643468 T LT 2643468T
Authority
LT
Lithuania
Prior art keywords
secretion
proteins
signal sequences
recombinant enzymes
improve protein
Prior art date
Application number
LTEP11843849.8T
Other languages
English (en)
Lithuanian (lt)
Inventor
Hung Do
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Publication of LT2643468T publication Critical patent/LT2643468T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002Antibodies with enzymatic activity, e.g. abzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2434Glucanases acting on beta-1,4-glucosidic bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022Alpha-galactosidase (3.2.1.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP11843849.8T 2010-11-22 2011-11-22 Naujos signalinės sekos, skirtos baltymo raiškos ir rekombinantinių fermentų ir kitų baltymų sekrecijos pagerinimui LT2643468T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41592610P 2010-11-22 2010-11-22
PCT/US2011/061862 WO2012071422A2 (en) 2010-11-22 2011-11-22 Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins

Publications (1)

Publication Number Publication Date
LT2643468T true LT2643468T (lt) 2018-09-10

Family

ID=46146394

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP11843849.8T LT2643468T (lt) 2010-11-22 2011-11-22 Naujos signalinės sekos, skirtos baltymo raiškos ir rekombinantinių fermentų ir kitų baltymų sekrecijos pagerinimui

Country Status (19)

Country Link
US (1) US9279007B2 (cg-RX-API-DMAC7.html)
EP (2) EP3461905B1 (cg-RX-API-DMAC7.html)
JP (1) JP2014503198A (cg-RX-API-DMAC7.html)
KR (2) KR101984318B1 (cg-RX-API-DMAC7.html)
CN (1) CN103328649B (cg-RX-API-DMAC7.html)
BR (1) BR112013012671B1 (cg-RX-API-DMAC7.html)
CA (1) CA2818689C (cg-RX-API-DMAC7.html)
CY (1) CY1121049T1 (cg-RX-API-DMAC7.html)
DK (2) DK3461905T3 (cg-RX-API-DMAC7.html)
ES (2) ES2829199T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20181315T1 (cg-RX-API-DMAC7.html)
HU (1) HUE039070T2 (cg-RX-API-DMAC7.html)
LT (1) LT2643468T (cg-RX-API-DMAC7.html)
PL (1) PL2643468T3 (cg-RX-API-DMAC7.html)
PT (1) PT2643468T (cg-RX-API-DMAC7.html)
RS (1) RS57601B1 (cg-RX-API-DMAC7.html)
SI (1) SI2643468T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800466T1 (cg-RX-API-DMAC7.html)
WO (1) WO2012071422A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3164492B1 (en) * 2014-07-03 2019-10-23 F. Hoffmann-La Roche AG Polypeptide expression systems
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
MY198804A (en) 2017-06-07 2023-09-28 Regeneron Pharma Compositions and methods for internalizing enzymes
CN111936624A (zh) * 2017-11-30 2020-11-13 阿米库斯治疗学公司 Cdkl5表达变体和cdkl5融合蛋白
BR112020016005A2 (pt) 2018-02-07 2020-12-15 Regeneron Pharmaceuticals, Inc. Método de administração de uma proteína terapêutica ao sistema nervoso central, proteína terapêutica multidomínio, polinucleotídeo, vetor de terapia gênica, e, uso de um nucleotídeo que codifica a proteína terapêutica multidomínio
TWI808169B (zh) 2018-04-30 2023-07-11 美商阿米庫斯醫療股份有限公司 基因治療構築體及使用方法
CN112135624B (zh) 2018-05-17 2024-07-19 瑞泽恩制药公司 抗cd63抗体、缀合物和其用途
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CA3115944A1 (en) 2018-10-10 2020-04-16 Amicus Therapeutics, Inc. Disulfide bond stabilized polypeptide compositions and methods of use
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
CN120519489A (zh) * 2018-12-19 2025-08-22 维萨梅布有限公司 编码蛋白质的rna
CA3132840A1 (en) 2019-03-08 2020-09-17 Obsidian Therapeutics, Inc. Human carbonic anhydrase 2 compositions and methods for tunable regulation
AU2020266829A1 (en) * 2019-04-30 2021-11-11 The Trustees Of The University Of Pennsylvania Compositions useful for treatment of Pompe disease
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
CN114450308A (zh) 2019-06-12 2022-05-06 黑曜石疗法公司 用于调节性调控的ca2组合物和方法
US20220348937A1 (en) 2019-09-06 2022-11-03 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
CN112342247B (zh) * 2020-11-10 2022-03-11 江苏科技大学 一种提高家蚕细胞表达外源蛋白分泌率的方法
EP4255500A1 (en) 2020-12-01 2023-10-11 The Trustees of The University of Pennsylvania Compositions and uses thereof for treatment of angelman syndrome
WO2023086939A1 (en) 2021-11-12 2023-05-19 Amicus Therapeutics, Inc. Compositions and methods for treating mucopolysaccharidosis iiia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4892132B2 (ja) * 1998-11-24 2012-03-07 ブリストル−マイヤーズ スクイブ カンパニー 70kD熱ショック蛋白による化合物の細胞内標的輸送
EP1689766B1 (en) * 2003-11-06 2012-04-25 Danisco US Inc. Expression in filamentous fungi of protease inhibitors and variants thereof
US20100222554A1 (en) * 2006-04-11 2010-09-02 Thomas Weimer Method of Increasing the In Vivo Recovery of Therapeutic Polypeptides

Also Published As

Publication number Publication date
CA2818689A1 (en) 2012-05-31
WO2012071422A3 (en) 2012-08-02
EP2643468A2 (en) 2013-10-02
BR112013012671B1 (pt) 2022-03-03
ES2829199T3 (es) 2021-05-31
CY1121049T1 (el) 2019-12-11
PL2643468T3 (pl) 2018-11-30
US20140045216A1 (en) 2014-02-13
EP2643468A4 (en) 2014-12-24
JP2014503198A (ja) 2014-02-13
CN103328649A (zh) 2013-09-25
PT2643468T (pt) 2018-10-11
DK3461905T3 (da) 2020-11-02
SI2643468T1 (sl) 2018-10-30
EP3461905B1 (en) 2020-08-05
HUE039070T2 (hu) 2018-12-28
EP3461905A1 (en) 2019-04-03
CN103328649B (zh) 2016-06-22
BR112013012671A2 (pt) 2016-10-11
SMT201800466T1 (it) 2018-11-09
US9279007B2 (en) 2016-03-08
DK2643468T3 (en) 2018-09-24
HRP20181315T1 (hr) 2018-10-19
WO2012071422A2 (en) 2012-05-31
EP2643468B1 (en) 2018-07-04
KR101984318B1 (ko) 2019-05-31
RS57601B1 (sr) 2018-11-30
KR20130121878A (ko) 2013-11-06
CA2818689C (en) 2021-09-21
KR20190060888A (ko) 2019-06-03
ES2687415T3 (es) 2018-10-25

Similar Documents

Publication Publication Date Title
SI2643468T1 (sl) Nova signalna zaporedja, za izboljšanje izražanje proteinov in izločanje rekombinantnih encimov in drugih proteinov
PL3211077T3 (pl) Sposoby oczyszczania rekombinowanego adamts13 i innych białek oraz ich kompozycje
EP2539473B8 (en) Modified proteins and methods of making and using same
IL207402A (en) Units for fermentation and process for making recombinant proteins
EP2547771B8 (en) Production of proteins and polypeptides
DK2552242T4 (da) Modermælkserstatning med lavt proteinindhold og med forøgede væsentlige aminosyrer
IL211740A0 (en) Recombinant proteins having haemostatic activity and capable of inducing platelet aggregation
IN2012DN06277A (cg-RX-API-DMAC7.html)
EP2553102A4 (en) HIGH PERFORMANCE EXPRESSION OF RECOMBINANT TOXIN PROTEINS
ZA201302939B (en) Expression vector for high level expression of recombinant proteins
HRP20150935T1 (en) Conjugation process of bacterial polysaccharides to carrier proteins
EP2649178B8 (en) Mgmt-based method for obtaining high yield of recombinant protein expression
EP2629788A4 (en) USE OF HUMAN SERUM ALBUMIN TO REDUCE THE ANTIGENICITY OF THERAPEUTIC PROTEINS
IL216619A0 (en) Recombinant production of peptides
SG10201502139XA (en) Method of Producing Recombinant Proteins with Mannose-Terminated N-Glycans
EP2519636B8 (en) Production of hemagglutinin-neuraminidase protein in microalgae
SMT201600147B (it) Metodi per migliorare l'espressione di proteine ricombinanti
IL216543A (en) Methods for enhancing production of human recombinant wild strain of beta-glucosidase
ZA201205271B (en) Predicting and reducing alloimmunogenicity of protein therapeutics
EP2598636A4 (en) VECTORS AND METHODS FOR EXPRESSION OF RECOMBINANT PROTEINS
IL232759A0 (en) A method for the increased expression of a recombinant protein of bacterial engineering and its use
DK2547694T5 (da) Hidtil ukendt signalpeptid og anvendelse deraf til fremstilling af rekombinante proteiner
IN2012DN03358A (cg-RX-API-DMAC7.html)
WO2010108182A3 (en) Production of recombinant proteins in ciliates and uses thereof
EP2600891A4 (en) PROTEIN FUSION CONSTRUCTS WITH THROMBOLYSIS AND AGING-INHIBITORY PROPERTIES